Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Sees Significant Increase in Short Interest


Share on StockTwits

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 4,090,000 shares, a growth of 29.4% from the March 31st total of 3,160,000 shares. Currently, 4.3% of the shares of the company are short sold. Based on an average daily trading volume, of 2,020,000 shares, the days-to-cover ratio is presently 2.0 days.

In other news, EVP Joseph Todisco sold 36,330 shares of the firm’s stock in a transaction dated Monday, March 15th. The stock was sold at an average price of $6.82, for a total value of $247,770.60. Following the transaction, the executive vice president now owns 316,270 shares of the company’s stock, valued at $2,156,961.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 26.32% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in the company. Victory Capital Management Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 944.0% in the 1st quarter. Victory Capital Management Inc. now owns 1,787,662 shares of the company’s stock worth $12,031,000 after purchasing an additional 1,616,423 shares during the period. Nkcfo LLC purchased a new position in shares of Amneal Pharmaceuticals in the 1st quarter worth approximately $229,000. Hussman Strategic Advisors Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 46.3% in the 1st quarter. Hussman Strategic Advisors Inc. now owns 180,000 shares of the company’s stock worth $1,211,000 after purchasing an additional 57,000 shares during the period. Virginia Retirement Systems ET AL boosted its holdings in shares of Amneal Pharmaceuticals by 189.1% in the 1st quarter. Virginia Retirement Systems ET AL now owns 116,500 shares of the company’s stock worth $784,000 after purchasing an additional 76,200 shares during the period. Finally, LSV Asset Management boosted its holdings in shares of Amneal Pharmaceuticals by 15.7% in the 1st quarter. LSV Asset Management now owns 1,263,600 shares of the company’s stock worth $8,504,000 after purchasing an additional 171,800 shares during the period. Hedge funds and other institutional investors own 33.49% of the company’s stock.

NYSE AMRX traded down $0.09 during trading on Tuesday, hitting $5.71. 1,386,424 shares of the stock traded hands, compared to its average volume of 1,822,961. The company has a market capitalization of $1.71 billion, a P/E ratio of 14.15, a price-to-earnings-growth ratio of 0.29 and a beta of 1.27. The firm has a 50-day simple moving average of $6.26 and a 200-day simple moving average of $5.14. The company has a quick ratio of 1.60, a current ratio of 2.31 and a debt-to-equity ratio of 8.20. Amneal Pharmaceuticals has a 12-month low of $3.37 and a 12-month high of $7.45.

Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings results on Thursday, February 25th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.01. The business had revenue of $510.00 million during the quarter, compared to analysts’ expectations of $506.91 million. Amneal Pharmaceuticals had a return on equity of 42.02% and a net margin of 3.30%. The firm’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.08 EPS. As a group, research analysts predict that Amneal Pharmaceuticals will post 0.56 EPS for the current fiscal year.

Several analysts recently issued reports on the company. Piper Sandler lifted their target price on Amneal Pharmaceuticals from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Friday, March 19th. Guggenheim lifted their target price on Amneal Pharmaceuticals from $6.50 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, April 14th. Zacks Investment Research downgraded Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 17th. The Goldman Sachs Group raised Amneal Pharmaceuticals from a “sell” rating to a “buy” rating and lifted their target price for the company from $4.00 to $6.50 in a research note on Monday, March 15th. Finally, Barclays lifted their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, March 1st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Amneal Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $6.93.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Article: How accurate is the Rule of 72?

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.